Orgenesis, SCTbio Partner to Expand POCare Sites in Czech Republic

Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGT) through its U.S.-based point-of-care (POCare) services subsidiary, Morgenesis LLC, entered into a collaborative agreement with SCTbio, a full-service contract development and manufacturing organization (CDMO) specializing in cell-based therapy and viral vectors.

The aim of the collaboration is to open new point-of-care (POCare) sites within the Czech Republic and leverage SCTbio’s GMP facility for the production of lentivirus vectors to support Morgenesis’ POCare worldwide customers, including use in CAR-T cell and gene therapies (CGTs).

Orgenesis’ POCare Platform, including its Orgenesis Mobile Processing Units and Labs (OMPULs), overcomes conventional processing challenges by enabling high-quality standards and sterile, scalable onsite processing of CGTs, near local hospitals and treatment facilities. The POCare centers and OMPULs are designed to shorten the implementation time of new production, while offering a more cost-effective environment and enabling local scalability.

Lentiviral vectors are part of the family of retroviral vectors and are a fundamental component of the cell therapy manufacturing process, ensuring the delivery of the therapeutic genes into the patient’s cells. SCTbio brings expertise in retroviral vector GMP production with a deep knowledge of state-of-the-art manufacturing technologies and quality control (QC) methods.

Ludek Sojka, CEO of SCTbio, said, “We are looking forward to collaborating with Orgenesis. Its POCare Platform is a unique technology supporting the development of potentially breakthrough CGTs, and we recognize the great potential for utilizing the long-term experience of our team and our GMP lentiviral vector manufacturing capabilities to support Orgenesis-powered breakthroughs in Central Europe and beyond.”

Vered Caplan, CEO of Orgenesis, said, “This partnership reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost-effective, high-quality, and scalable manner. We look forward to teaming with SCTbio to expand our POCare CGT production services to the region, as well as leveraging their lentiviral vector production as a key element supporting our CAR-T customers in the EU.”